---
title: "中國生物製藥稱，國家藥品監督管理局已批准 Benmelstobart 注射液上市"
description: "中國生物製藥表示，國家藥品監督管理局已批准 Benmelstobart 注射劑上市"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276024005.md"
published_at: "2026-02-16T02:05:56.000Z"
---

# 中國生物製藥稱，國家藥品監督管理局已批准 Benmelstobart 注射液上市

> 中國生物製藥表示，國家藥品監督管理局已批准 Benmelstobart 注射劑上市

### Related Stocks

- [516820.CN - 平安中證醫療創新ETF](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [159102.CN - 華安恆生生物科技ETF](https://longbridge.com/zh-HK/quote/159102.CN.md)
- [589720.CN - 國泰上證科創板創新藥ETF](https://longbridge.com/zh-HK/quote/589720.CN.md)
- [516500.CN - 華夏中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [01177.HK - 中國生物制藥](https://longbridge.com/zh-HK/quote/01177.HK.md)
- [159929.CN - 匯添富中證醫藥衞生ETF](https://longbridge.com/zh-HK/quote/159929.CN.md)
- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [512290.CN - 國泰中證生物醫藥ETF](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [588250.CN - 鵬華上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [560600.CN - 方正富邦中證醫藥及醫療器械創新ETF](https://longbridge.com/zh-HK/quote/560600.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |
| Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | [Link](https://longbridge.com/zh-HK/news/275387692.md) |
| Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer | Shanghai Henlius Biotech Inc. has initiated a phase 1b/2 clinical trial for HLX43, an anti-PD-L1 antibody-drug conjugate | [Link](https://longbridge.com/zh-HK/news/275577160.md) |
| Nanjing Leads Biolabs Doses First Patient in Phase Ib/II Trial of Opamtistomig for Metastatic Triple-Negative Breast Cancer | Nanjing Leads Biolabs Co., Ltd. has initiated a Phase Ib/II clinical trial for its drug Opamtistomig, targeting recurren | [Link](https://longbridge.com/zh-HK/news/275425267.md) |
| WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/zh-HK/news/275670240.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。